

**North Dakota Department of Human Services
Summary of Drug Utilization Review Board Recommendations
On Managing Utilization of Identified Drug Classes Currently Restricted
2007 House Bill 1422 Report**

The 2007 Legislature, through House Bill No. 1422, asked the Drug Use Review (DUR) Board to review the utilization, cost, and effectiveness of the drugs identified in subsection 3 of section 50-24.6-04 and make recommendations for managing the utilization of the identified drugs or any other drugs for the conditions identified in that subsection.

The classes of medications reviewed include Oncology, HIV/AIDS, Attention Deficit/Hyperactivity Disorder (ADHD), Antidepressants, Antipsychotics, and Mood Stabilizers/Anticonvulsants. Antipsychotics, Mood Stabilizers/Anticonvulsants, Antidepressants and ADHD medications are the top four classes of medications (by cost) paid by ND Medicaid.

1. HIV/AIDS-DUR Board consulted with an Infectious Disease Specialist. His opinion was that ND Medicaid should not prior authorize any HIV/AIDS medication, but he did not believe that a law should exist to prohibit action in the future-specifically if a physician prescribed outside of the AIDS Drug Assistance Program (ADAP) guidelines. The DUR Board concurred with the Infectious Disease Specialist's opinion.
2. Oncology-DUR Board consulted with an Oncologist. Specialist stated that no law was needed to prevent antineoplastics from being placed on prior authorization as long as recommendations for PA come from the DUR Board and that the turnaround time for PA's also remained the same (98% reviewed in 8 hours or less and 100% in 24 hours). The DUR Board recommended that antineoplastics no longer be exempt from prior authorization and that the DUR Board be involved in the PA of certain agents using private insurance as a guideline.
3. Attention Deficit/Hyperactivity Disorder (ADHD)-DUR Board recommended removing the exemption for this class, prior authorizing Vyvanse after Adderall XR trial, and prior authorizing Daytrana.
4. Antidepressants-DUR Board recommended placing certain SSRI medications on prior authorization and therefore removing the exemption for the antidepressant class of medications.
5. Antipsychotics-DUR Board recommended prior authorizing alternate dosage forms and Invega if the exemption was removed from this class of medications.
6. Anticonvulsants-DUR Board made no recommendation on the Anticonvulsant class of medications.